tetano
Editor, Senior Moderator
Bone Marrow Transplant
. 2021 Apr 27.
doi: 10.1038/s41409-021-01312-y. Online ahead of print.
Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East
Riad El Fakih[SUP] 1 [/SUP], Alfadil Haroon[SUP] 2 [/SUP], Feras Alfraih[SUP] 2 [/SUP], Murtadha K Al-Khabori[SUP] 3 [/SUP], Mohsen Alzahrani[SUP] 4 5 6 [/SUP], Ahmad Alhuraiji[SUP] 7 [/SUP], Abdulaziz Hamadah[SUP] 7 [/SUP], Naif I AlJohani[SUP] 2 [/SUP], Bader Alahmari[SUP] 4 5 6 [/SUP], Mohammed F Essa[SUP] 5 6 8 [/SUP], Ibraheem H Motabi[SUP] 9 [/SUP], Imran K Tailor[SUP] 9 [/SUP], Reem S Almaghrabi[SUP] 2 [/SUP], Khalil Al-Farsi[SUP] 3 [/SUP], Ibraheem Abosoudah[SUP] 2 [/SUP], Mouhab Ayas[SUP] 2 [/SUP], Tusneem A Elhassan[SUP] 2 [/SUP], Ashraf M Suhebeh[SUP] 10 [/SUP], Syed Osman Ahmed[SUP] 2 [/SUP], Saud Alhayli[SUP] 2 [/SUP], Panayotis Kaloyannidis[SUP] 10 [/SUP], Ahmad Alsaeed[SUP] 6 11 [/SUP], Khalid Al Anezi[SUP] 10 [/SUP], Sameer Alamoudi[SUP] 6 11 [/SUP], Moussab Damlaj[SUP] 4 5 6 [/SUP], Hani Al Hashmi[SUP] 10 [/SUP], Mahmoud Aljurf[SUP] 2 [/SUP]
Affiliations
Abstract
The coronavirus disease-2019 (COVID-19) caused by SARS Coronavirus 2 (SARS-CoV-2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection. We aimed to study the COVID-19 outcomes and severity in post HCT patients. We retrospectively reviewed post-HCT patients diagnosed with COVID-19 between March 15, 2020, and December 1, 2020 at 10 transplant centers across the Middle East. We identified 91 patients with confirmed SARS-CoV-2 infection across 10 transplant centers. The median age upon presentation with COVID-19 was 35. Fifty two patients were post allo-HCT while the remaining 39 patients were post auto-HCT. The median time from transplant was 14.9 months. Mortality rate was 4.4%. Hospital admission rate was 53%. ICU admission rate was 14%. Mechanical ventilation rate was 10%. Oxygen supplementation rate was 18%. Time from HCT to COVID-19 >6 months was associated with lower admission rates and lower rates of the "severity" composite endpoint. Antibody responses was seen 67% of evaluable patients. In this series of HCT recipients, we report overall favorable clinical outcomes for patients with COVID-19 and provide preliminary insights into the clinical course of this disease in this specific population.
. 2021 Apr 27.
doi: 10.1038/s41409-021-01312-y. Online ahead of print.
Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East
Riad El Fakih[SUP] 1 [/SUP], Alfadil Haroon[SUP] 2 [/SUP], Feras Alfraih[SUP] 2 [/SUP], Murtadha K Al-Khabori[SUP] 3 [/SUP], Mohsen Alzahrani[SUP] 4 5 6 [/SUP], Ahmad Alhuraiji[SUP] 7 [/SUP], Abdulaziz Hamadah[SUP] 7 [/SUP], Naif I AlJohani[SUP] 2 [/SUP], Bader Alahmari[SUP] 4 5 6 [/SUP], Mohammed F Essa[SUP] 5 6 8 [/SUP], Ibraheem H Motabi[SUP] 9 [/SUP], Imran K Tailor[SUP] 9 [/SUP], Reem S Almaghrabi[SUP] 2 [/SUP], Khalil Al-Farsi[SUP] 3 [/SUP], Ibraheem Abosoudah[SUP] 2 [/SUP], Mouhab Ayas[SUP] 2 [/SUP], Tusneem A Elhassan[SUP] 2 [/SUP], Ashraf M Suhebeh[SUP] 10 [/SUP], Syed Osman Ahmed[SUP] 2 [/SUP], Saud Alhayli[SUP] 2 [/SUP], Panayotis Kaloyannidis[SUP] 10 [/SUP], Ahmad Alsaeed[SUP] 6 11 [/SUP], Khalid Al Anezi[SUP] 10 [/SUP], Sameer Alamoudi[SUP] 6 11 [/SUP], Moussab Damlaj[SUP] 4 5 6 [/SUP], Hani Al Hashmi[SUP] 10 [/SUP], Mahmoud Aljurf[SUP] 2 [/SUP]
Affiliations
- PMID: 33907304
- DOI: 10.1038/s41409-021-01312-y
Abstract
The coronavirus disease-2019 (COVID-19) caused by SARS Coronavirus 2 (SARS-CoV-2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection. We aimed to study the COVID-19 outcomes and severity in post HCT patients. We retrospectively reviewed post-HCT patients diagnosed with COVID-19 between March 15, 2020, and December 1, 2020 at 10 transplant centers across the Middle East. We identified 91 patients with confirmed SARS-CoV-2 infection across 10 transplant centers. The median age upon presentation with COVID-19 was 35. Fifty two patients were post allo-HCT while the remaining 39 patients were post auto-HCT. The median time from transplant was 14.9 months. Mortality rate was 4.4%. Hospital admission rate was 53%. ICU admission rate was 14%. Mechanical ventilation rate was 10%. Oxygen supplementation rate was 18%. Time from HCT to COVID-19 >6 months was associated with lower admission rates and lower rates of the "severity" composite endpoint. Antibody responses was seen 67% of evaluable patients. In this series of HCT recipients, we report overall favorable clinical outcomes for patients with COVID-19 and provide preliminary insights into the clinical course of this disease in this specific population.